Allogeneic hematopoietic cell transplant (HCT) has improved survival of patients with leukemia, but relapse remains the major cause of treatment failure. The infusion of donor lymphocytes to treat relapse after HCT has formally demonstrated benefits of lymphocyte-mediated anti-leukemic activity, but the polyclonal T cells recognize proteins expressed by many host tissues as well as leukemia, resulting in morbidity/mortality from graft-versus-host disease. Thus, generating and administering T cells specific for proteins preferentially expressed by leukemic cells has potential to not only impact survival but provide a platform for developing T cell therapy as a more effective, less toxic therapeutic modality. WT1, a pro-oncogenic transcription factor with very limited expression in nonrial adult tissues, is detected at high levels in leukemic cells and many other malignancies. We have shown that WTI-specific CD8 T cells, generated from HCT donors, expanded ex vivo, and transferred into relapsed patients, can exhibit anti-leukemic activity with no evidence of toxicity to normal tissues, but most patients progress in part due to failure to achieve large magnitude T cell responses of high avidity that can persist to eradicate leukemia. Similar obstacles have been observed with WT1 vaccines. These problems may be addressable by employing lentiviral vectors to insert high affinity TCR genes isolated from a WT1-specific CD8 T cell done into large numbers of donor memory CD8 T cells with limited ex vivo expansion. The proposed studies will: 1) evaluate in a Phase l/ll trial safety and potential efficacy for preventing relapse in HCT patients at high risk for recurrence of infusing donor-derived EBV specific CD8 T cells transduced to express a high affinity TCR specific for WT1;2) evaluate in a Phase l/ll trial potential limitations to anti-leukemic activity of infusions of these transduced WTI-specific CDS T cells into patients who have relapsed after HCT;and 3) generate and screen for safety/activity a panel of mutated human TCRs with a range of increased affinities for WT1 as a means to overcome obstacles to efficacy in future trials for leukemia and other tumors. These studies using novel reagents/methods should impact fields of T cell and gene therapy and demonstrate the potential of gene-modified T cells as therapeutic reagents.
Allogeneic hematopoietic cell transplantation (HCT) can cure a large fraction of patients with leukemia, but fatal relapse remains a major obstacle. The infusion of T cells that can selectively target residual leukemia cells represents a strategy with the potential to greatly improve the therapeutic benefit of HCT with limited toxicity. The proposed clinical trials and studies will evaluate a strategy in which T cells highly reactive with leukemia can be efficiently generated by genetic manipulation, and offers potential for broader application.
|Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629|
|Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562|
|Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313|
|Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764|
|Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531|
|Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580|
|Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541|
|McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807|
|Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193|
|Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515|
Showing the most recent 10 out of 1845 publications